Ivonescimab + Carboplatin + Docetaxel
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC
Conditions
TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Trial Timeline
Jul 25, 2025 → Nov 1, 2032
NCT ID
NCT07017673About Ivonescimab + Carboplatin + Docetaxel
Ivonescimab + Carboplatin + Docetaxel is a phase 2 stage product being developed by Summit Therapeutics for TNBC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07017673. Target conditions include TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in TNBC were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07017673 | Phase 2 | Recruiting |
Competing Products
14 competing products in TNBC